1,721,324 research outputs found
Amor, ch'al cor gentil ratto s'apprende : Erotomania, stalking, celebrity stalking
No full textGli Autori analizzano la correlazione fra stalking, erotomania e celebrity stalking, con particolare attenzione alla pericolosità sociale degli stalker erotomanici. Sono presentati due casi di celebrity stalking, uno dei quali basato su erotomania eterosessuale, l'altro omosessuale
High density lipoprotein administration: a new therapeutic modality for the treatment of cardiovascular diseases
No full textApolipoprotein A-I (apoA-I) is a 243 amino-acid cysteine deficient protein, containing 10 amphipathic domains, that allow its binding to a lipid-rich surface. It is the major protein component of high-density lipoproteins (HDL). Each HDL contains 2 or 3 copies of apoA-I plus various combinations of additional apolipoproteins (e.g. apoE, apoA-IV, apoA-II), lipid transport proteins (e.g. CETP and PLTP), and surface acting enzymes (e.g. paraoxonase, LCAT, PAF). This heterogenous and dynamic class of lipoproteins mainly functions in reverse cholesterol transport, a process resulting in the net removal of excess cholesterol from tissues, to be transported to the liver for excretion. The apolipoprotein A-IMilano (A-IMilano) is a rare and naturally occurring variant form of the native apoA-I. The A-IMilano variant was a chance discovery in an individual with very low HDL-cholesterol (7-10 mg/dL) compared to the normal human levels of 40-50 mg/dL. This clinical observation dates back 30 years, and was accompanied by similar findings in two of the proband’s children as well as in his father. Surprisingly, these carriers appeared to be remarkably free from any vascular abnormalities. Extensive studies led to the identification of the mutation, a Cysteine for Arginine substitution at position 173, i.e. the first description of a human apolipoprotein mutation associated to altered lipoprotein composition and metabolism. This led to an extensive evaluation of the population of Limone sul Garda for the presence of the mutation and the cardiovascular disease status of the population, confirming the earlier suggestion that this might be a protective variant. In the past 25 years some important additional insights were provided. Particularly, it could be shown that the HDL containing A-IMilano is endowed with a remarkably enhanced capacity to remove cholesterol from tissues.
“HDL therapy” is a novel and emerging area of therapeutic development in the cardiovascular field. It attempts to supplement and improve the vascular benefit exerted by other agents active on lipid metabolism, ie hypolipidemic drugs. Further, it takes advantage on novel techniques of coronary evaluation. A number or reports have examined the potential therapeutic properties of synthetic HDL prepared by complexing recombinant apo A-IMilano with phospholipids. The availability of synthetic HDL complexes containing recombinant apoA-IMilano has opened a new era of therapeutic management of coronary disease.
Prototype HDL formulations of recombinant apoA-IMilano/phospholipid complexes have used dipalmitoylphosphatidylcholine (DPPC) or 1-palmitoyl-2-oleyl phosphatidylcholine (POPC) as phospholipid component. HDL containing apoA-IMilano/DPPC have clearly shown rapid regression of a focal carotid atheroma in a rabbit model. The mechanism of this very rapid effect appears to be associated with the cholesterol removing capacity and extended serum half-life of HDL containing A-IMilano. In a pilot study, ETC-216 (apoA-IMilano/POPC) similarly showed significant reduction of coronary plaque burden after five weekly treatments as assessed by intravascular ultrasound (IVUS) in patients with acute coronary syndromes.
It is likely that additional safety, efficacy and dose regimen studies in a larger patient population will need to be performed to fully evaluate the potential of this agent as an “HDL therapy” product candidate. “HDL therapy” such as ETC-216 is being evaluated for use with the current standard of care for patients with acute coronary syndromes, including the use of statins
Il risarcimento del danno emergente per prestazioni di assistenza protesica in ambito civilistico.
No full textTherapeutic use of the high-density lipoprotein protein and peptides
No full textHigh-density lipoprotein (HDL) therapy is a novel and emerging area of therapeutic development in the cardiovascular field. It attempts to supplement and improve the vascular benefit exerted by other agents that are active on lipid metabolism, for example, hypolipidaemic drugs. Furthermore, it takes advantage of the novel techniques of coronary evaluation. A number of reports have examined the potential therapeutic properties of the synthetic HDLs prepared by complexing recombinant apolipoprotein (apo) A-IMilano, a variant form of native apoA-I, with phospholipids. The availability of synthetic HDL complexes containing recombinant apoA-IMilano has opened up a new era of therapeutic management for coronary disease. HDL formulations of recombinant apoA-IMilano-phospholipid complexes have clearly shown rapid regression of a focal carotid atheroma as well as powerful protection from myocardial infarction in a rabbit model. In a pilot study, ETC-216 showed a significant reduction in coronary plaque burden after five weekly treatments, assessed by intravascular ultrasound in patients with acute coronary syndrome. Other therapeutic options of HDL therapy have recently became available
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
A digital 'snake' implementation of the back-propagation neural networkIEEE International Symposium on Circuits and Systems
No full text- …
